Imaging genomic mapping in glioblastoma.

Thus, despite recent advances in novel sequenc-ing and microarray technologies that have led to profounddiscoveries and a better understanding of DNA- and RNA-based genomic alterations in cancer and the availability ofthese data to the scientific community, little progress inGBM therapy has been made, and the clinical course of dis-ease and everyday life of GBM patients remain largelyunchanged.

[1]  P. Kleihues,et al.  IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas , 2009, Clinical Cancer Research.

[2]  D. Le Bihan,et al.  Magnetic resonance imaging of perfusion , 1990 .

[3]  Peter A. Jones,et al.  Epigenetics in cancer. , 2010, Carcinogenesis.

[4]  A. Jemal,et al.  Cancer statistics, 2011 , 2011, CA: a cancer journal for clinicians.

[5]  Yan Ding,et al.  IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma , 2012, Cancer science.

[6]  J. Herman,et al.  Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. , 2000, Cancer research.

[7]  R. Turner,et al.  Diffusion MR imaging: clinical applications. , 1992, AJR. American journal of roentgenology.

[8]  E. Chiocca,et al.  Emerging functions of microRNAs in glioblastoma , 2009, Journal of Neuro-Oncology.

[9]  R. Jain,et al.  Correlation of Perfusion Parameters with Genes Related to Angiogenesis Regulation in Glioblastoma: A Feasibility Study , 2012, American Journal of Neuroradiology.

[10]  Henry Brem,et al.  Independent association of extent of resection with survival in patients with malignant brain astrocytoma. , 2009, Journal of neurosurgery.

[11]  Ovidiu C. Andronesi,et al.  Detection of 2-Hydroxyglutarate in IDH-Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy , 2012, Science Translational Medicine.

[12]  Paul S Mischel,et al.  Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis. , 2008, Radiology.

[13]  G. Reifenberger,et al.  Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. , 2012, The Lancet. Oncology.

[14]  Z L Gokaslan,et al.  A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. , 2001, Journal of neurosurgery.

[15]  Hong Wu,et al.  Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy , 2012, Journal of Neuro-Oncology.

[16]  B A Kall,et al.  Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. , 1987, Journal of neurosurgery.

[17]  J. Herman,et al.  Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Rich,et al.  Deadly teamwork: neural cancer stem cells and the tumor microenvironment. , 2011, Cell stem cell.

[19]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[20]  M. Berger,et al.  GLIOMA EXTENT OF RESECTION AND ITS IMPACT ON PATIENT OUTCOME , 2008, Neurosurgery.

[21]  K. Aldape,et al.  Identification of noninvasive imaging surrogates for brain tumor gene-expression modules , 2008, Proceedings of the National Academy of Sciences.

[22]  C. Waddington,et al.  REPRINTS AND REFLECTIONS , 2012 .

[23]  A. Verma.  MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma , 2006 .

[24]  R. McLendon,et al.  The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype , 2009, Cell cycle.

[25]  Kristina Potocki,et al.  The differences of water diffusion between brain tissue infiltrated by tumor and peritumoral vasogenic edema. , 2009, Clinical imaging.

[26]  T. Kipps,et al.  CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. , 2006, Blood.

[27]  Dinesh Rakheja,et al.  2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated glioma patients , 2011, Nature Medicine.

[28]  J. Rich,et al.  Potential therapeutic implications of cancer stem cells in glioblastoma. , 2010, Biochemical pharmacology.

[29]  Mitchel S Berger,et al.  An extent of resection threshold for newly diagnosed glioblastomas. , 2011, Journal of neurosurgery.

[30]  Frank J. Slack,et al.  The Role of MicroRNAs in Cancer , 2006, The Yale journal of biology and medicine.

[31]  William A. Flavahan,et al.  Glioma stem cell maintenance: the role of the microenvironment. , 2011, Current pharmaceutical design.

[32]  D LeBihan,et al.  Theoretical principles of perfusion imaging. Application to magnetic resonance imaging. , 1992 .

[33]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[34]  Glyn Johnson,et al.  Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. , 2004, AJNR. American journal of neuroradiology.

[35]  J. Costello,et al.  Epigenetic mechanisms in glioblastoma multiforme. , 2009, Seminars in cancer biology.

[36]  Ferenc A. Jolesz,et al.  Radiogenomic Mapping of Edema/Cellular Invasion MRI-Phenotypes in Glioblastoma Multiforme , 2011, PloS one.

[37]  G. Reifenberger,et al.  Predictive impact of MGMT promoter methylation in glioblastoma of the elderly , 2012, International journal of cancer.

[38]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[39]  Elias R Melhem,et al.  Advanced MR imaging techniques in the diagnosis of intraaxial brain tumors in adults. , 2006, Radiographics : a review publication of the Radiological Society of North America, Inc.

[40]  J. Uhm.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2009 .

[41]  Gi-Hwan Choi,et al.  (1)H-MRS metabolic patterns for distinguishing between meningiomas and other brain tumors. , 2003, Magnetic resonance imaging.

[42]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[43]  K. Hess,et al.  Identification of Necrosis-Associated Genes in Glioblastoma by cDNA Microarray Analysis , 2004, Clinical Cancer Research.

[44]  A. von Deimling,et al.  The Next Generation of Glioma Biomarkers: MGMT Methylation, BRAF Fusions and IDH1 Mutations , 2011, Brain pathology.

[45]  Waddington Ch,et al.  The epigenotype. 1942. , 2012 .

[46]  Pascal O. Zinn,et al.  A Novel Volume-Age-KPS (VAK) Glioblastoma Classification Identifies a Prognostic Cognate microRNA-Gene Signature , 2012, PloS one.